Kintara Therapeutics (KTRA)
(Delayed Data from NSDQ)
$0.15 USD
-0.01 (-5.82%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.14 -0.01 (-5.91%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
KTRA 0.15 -0.01(-5.82%)
Will KTRA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KTRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KTRA
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
KTRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KTRA
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Friday's After-Market Session
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Kintara Therapeutics Eyes Merger Amidst Clinical Trial Buzz
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)